Tafrali, C., Paizi, A., Borg, J., Radmilovic, M., Bartsakoulia, M., Giannopoulou, E., Giannakopoulou, O., Stojiljkovic-Petrovic, M., Zukic, B., Poulas, K., Stavrou, E. F., Lambropoulou, P., Kourakli, A., Felice, A. E., Papachatzopoulou, A., Philipsen, S., Pavlovic, S., Georgitsi, M., & Patrinos, G. P. (2013). genomic variation in the MAP3K5 gene is associated with β-thalassemia disease severity and hydroxyurea treatment efficacy. Pharmacogenomics, 14, 469–483. http://access.bl.uk/ark:/81055/vdc_100135874032.0x000015